Hazard Ratio | 95% Confidence interval | P | |
---|---|---|---|
Traditional risk factors | |||
Age univariate | 2.28* | 1.67 to 2.10 | < 0.0001 |
Age adjusted | |||
Male gender | 0.71 | 0.11 to 2.41 | |
Smoking, ever | 2.62 | 1.11 to 7.03 | 0.03 |
Hypertension | 0.72 | 0.30 to 1.70 | |
Systolic blood pressure | 0.78 | 0.52 to 1.18 | |
Hypercholesterolemia | 1.37 | 0.61 to 3.14 | |
Total cholesterol | 1.19 | 0.81 to 1.74 | |
LDL | 1.23 | 0.80 to 1.89 | |
HDL | 0.77 | 0.34 to 1.62 | |
Triglycerides† | 1.21 | 0.86 to 1.69 | |
ApoB/ApoA† | 1.36 | 0.88 to 2.10 | |
Diabetes | ‡ | ‡ | 0.02 |
Manifestations of Lupus | |||
Disease duration | 1.28 | 0.98 to 1.68 | |
Malar rash | 1.09 | 0.72 to 1.67 | |
Discoid lupus | 0.80 | 0.45 to 1.26 | |
Photosensitivity | 0.69 | 0.46 to 1.04 | |
Oral ulcers | 1.40 | 0.90 to 2.14 | |
Arthritis | § | § | 0.002 |
Pleuritis | 1.60 | 1.02 to 2.46 | 0.04 |
Pericarditis | 1.35 | 0.77 to 2.16 | |
Nephritis | 1.31 | 0.85 to 1.97 | |
Leukopenia | 0.94 | 0.62 to 1.42 | |
Thrombocytpenia | 0.37 | 0.09 to 0.83 | 0.009 |
Neurologic disorder | 0.78 | 0.48 to 1.44 | |
Previous venous occlusion | 1.88 | 1.16 to 2.90 | 0.01 |
SLICC>1 | 1.91 | 0.74 to 5.97 | |
SLAM>6 at baseline | 1.25 | 0.83 to 1.87 | |
Medications | |||
Months on steroid treatment | 1.00 | 0.68 to 1.48 | |
Cyclofosfamide treatment ever | 0.60 | 0.01 to 2.03 | |
Azathioprine at baseline | 0.51 | 0.03 to 2.47 | |
Chloroquine/Hydroxychloroquine at baseline | 1.01 | 0.32 to 2.67 | |
Warfarin at baseline | 1.45 | 0.34 to 4.27 | |
ASA at baseline | 1.54 | 0.55 to 3.70 | |
Autoantibodies against | |||
dsDNA | 1.41 | 0.57 to 3.25 | |
CL IgG | 2.57 | 1.13 to 6.13 | 0.02 |
CL IgM | 1.35 | 0.45 to 3.41 | |
β2GP1 IgG | 2.57 | 1.13 to 5.99 | 0.02 |
Lupus anticoagulant | 1.10 | 0.40 to 2.63 | |
Any aPL | 4.90 | 1.76 to 17.72 | 0.002 |
SSA | 0.66 | 0.39 to 1.03 | |
SSB | 0.57 | 0.27 to 1.00 | 0.05 |
Sm | 1.21 | 0.48 to 2.29 | |
RNP | 1.60 | 0.76 to 2.87 | |
Markers of systemic inflammation | |||
hs CRP† | 1.36 | 0.85 to 2.18 | |
Fibrinogen† | 1.72 | 1.10 to 2.68 | 0.02 |
α-1 antitrypsine | 1.49 | 1.01 to 2.18 | |
SAA† | 1.36 | 0.88 to 2.09 | |
IL 6† | 1.26 | 0.87 to 1.82 | |
C3 | 0.92 | 0.63 to 1.35 | |
C3d | 1.38 | 0.85 to 2.22 | |
C4 | 0.82 | 0.56 to 1.18 | |
Markers of endothelial activation | |||
sVCAM-1† | 1.78 | 1.20 to 2.65 | 0.005 |
von Willebrand factor† | 2.05 | 1.23 to 3.42 | 0.004 |
Markers of renal involvement | |||
Creatinine† | 1.17 | 0.74 to 1.85 | |
MDRD | 1.07 | 0.57 to 2.00 | |
Blood urea nitrogen | 1.15 | 0.75 to 1.77 | |
Pathological urine | 2.4 | 0.8 to 6.1 | |
Other biomarkers | |||
Albumin(g/l) | 0.56 | 0.41 to 0.78 | 0.002 |
Homocystein (μmol/l)† | 0.79 | 0.52 to 1.21 |